ImmuneBridge
Sumiti Jain is an accomplished scientific leader with extensive experience in immunology and oncology. Currently serving as Chief Scientific Officer at ImmuneBridge since March 2024, Jain previously held the role of VP, Head of R&D at Inceptor Bio and at Stealth Mode Biotech. Jain's expertise includes leading immuno-oncology initiatives as Director at Poseida Therapeutics, Inc. and Associate Director at Sangamo Therapeutics, Inc. Early career highlights include significant contributions at Juno Therapeutics, Inc. and a post-doctoral fellowship at The National Institutes of Health. Jain earned a Ph.D. in Immunology and Virology from McMaster University.
This person is not in any teams
This person is not in any offices
ImmuneBridge
ImmuneBridge is developing allogeneic immunotherapies for cancer. ImmuneBridge's key innovation fosters the development of immune stem cells obtained from cord blood and creates a fresh, adaptable, reliable, and plentiful cellular source for immunotherapies. They are currently looking for natural killer cell-based treatments for hematologicalcancers. They will then attack solid tumors using the special benefits of their cellular source.